AzTrials
AzTrials

Smoking CessationNCT06303089

Tobacco Exposure and Influencing Factors of Smoking Cessation Among Chronic Kidney Disease Patients

An observational study of Smoking Cessation, run by Sun Yat-sen University at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to describe the tobacco exposure and characteristics of patients with Chronic Kidney Disease (CKD) who quit smoking, to identify patients' tobacco-related knowledge, attitude, and practice (KAP) and explore the influencing factors of smoking cessation. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Smoking Cessation
What is being tested?
Questionnaires set
How many people
567 participants
Where
1 siteChina
Study dates
5 Apr 2024to 15 Apr 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Chronic Kidney Disease Patients

Who may be able to join

  • Participants aged 18 years or older;
  • Participants with a confirmed diagnosis of Chronic Kidney Disease;
  • Participants were able to speak and read Chinese.;

Who cannot join

  • Participants who with psychiatric illness, disorders of consciousness, communication impairments, were unable to communicate effectively;
  • Participants who have acute and life-threatening exacerbations which require urgent treatment;
  • Patients who currently involved in other smoking cessation programs.

Trial locations and contacts

1 site in 1 country.

China1 site
  • XIAW

    Guangzhou, Guangdong, 510080

Other trials in China

About this study

Official title: Tobacco Exposure and Influencing Factors of Smoking Cessation Among Chronic Kidney Disease Patients: A Cross-Sectional Study.

The purpose of this study is to describe the tobacco exposure and characteristics of patients with Chronic Kidney Disease (CKD) who quit smoking, to identify patients' tobacco-related knowledge, attitude, and practice (KAP) and explore the influencing factors of smoking cessation.

Read the detailed description

Participants will be invited to recall their smoking status and tobacco-related KAP. Smokers need to identify their smoking cessation behavior.

First part: participants need to finish the questionnaire, which includes the demographic information sheet, characteristics of smoking sheet, and tobacco-related KAP. Including (a) patients' knowledge of health risks of tobacco and tobacco-related diseases (the delphi method was used to construct this knowledge questionnaire); and (b) perceptions of tobacco harm.

Second part: smokers need to finish the questionnaire, which includes history of smoking cessation sheet, attitudes towards tobacco control smoking cessation, nicotine dependence sheet, tobacco withdrawal symptoms sheet, intention to quit smoking sheet, ability to quit smoking sheet, alcohol use disorders and physical activity.

Being tested
Questionnaires set
Keywords
Chronic kidney disease, Smoking cessation behavior, Cross-sectional study, Tobacco-related knowledge, attitudes, and practice, Tobacco exposure
Medical subject headings
Smoking Cessation, Renal Insufficiency, Chronic, Behavior

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Questionnaires setOther

    Participants will be asked to respond to the demographic information sheet, characteristics of smoking sheet, tobacco-related knowledge, perceptions of tobacco harm. Smokers will be asked the history of smoking cessation sheet, the Fagerstrom Test of Nicotine Dependence, Smoking Self-efficacy Questionnaire, Cigarette Withdrawal Scale, Intention to Quit Smoking sheet, Motivation to Quit Smoking sheet, Alcohol Use Disorders Identification Test, and International Physical Activity Questionnaire.

Study groups in NCT06303089
Study groupRoleWhat they receive
Questionnaires assessed Chronic Kidney Disease patientsParticipants who met the inclusion criteria below will be invited to fill in tobacco exposure questionnaires, smokers will be invited to complete smoking cessation questionnaires set. 1. Participants aged 18 years or older; 2. Participants with a confirmed diagnosis of Chronic Kidney Disease;
Receives: Other: Questionnaires set

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Prevalence of current smokers

    A true or false sheet in the questionnaire.

    Measured: Baseline

  2. Abstinence rates

    A true or false sheet in the questionnaire.

    Measured: Baseline

Secondary outcomes (6)
  1. Nicotine dependence

    The Fagerstrom Test for Nicotine Dependence (FTND) was applied to assess nicotine dependence, which has a set of 6 items with an overall score ranging from 0-10. High dependence was defined as an FTND score ≥7; medium dependence, a score ranging from 4-6; low dependence, a score ranging from 0-3.

    Measured: Baseline

  2. Perceptions of tobacco harm

    Knowledge of health hazards of active and passive smoking was applied to assess perceptions of tobacco harm. The questionnaire has a set of 17 items which was developed according to the literature review content. Participants were asked to answer whether the knowledge about tobacco harm contained in the entry is correct: yes, no, or don't know. the higher percentages of correct responses to each item of the knowledge subscale means the better mastery of self-awareness of the hazard of smoking.

    Measured: Baseline

  3. knowledge of tobacco-related diseases

    Tobacco-related chronic kidney disease (CKD) was applied to assess knowledge of tobacco-related diseases. The questionnaire has a set of 23 items which was developed according to the literature review content (The delphi method was used to construct this knowledge level questionnaire). This questionnaire was categorized into three subscales, namely cigarette smoking increases the risk of CKD (15 items), e-cigarettes and nephrotoxicity (2 items) and health benefits of smoking cessation for patients with CKD (6 items), with the answer: know, know a little, do not know or not sure. Higher scores of both subscales indicate the greater mastery of knowledge of tobacco-related diseases.

    Measured: Baseline

  4. Smoking related attitudes

    Smoking Rationalization Beliefs (SRBs) refer to the relevant attitudes that smokers use to rationalize their smoking behavior and maintain their smoking status. The simplification of the scale with 8 items, each question use a five-point likert scale with 1 being 'strongly agree' and 5 being 'strongly disagree'. The higher the score was, the lower the SRBs.

    Measured: Baseline

  5. Self-efficacy level

    Smoking Self-Efficacy Questionnaire (SEQ-12) was applied to assess the self-efficacy level. The SEQ-12 is a self-report inventory consisting of 12 items measuring the confidence of current and exsmokers in their ability to abstain from smoking in high-risk situations. The instrument is intended to measure two dimensions: internal stimuli (6 items) and external stimuli (6 items). Responses were solicited with a five-point Likert scale ranging from 1=not at all sure to 5=absolutely sure, where greater values indicated that the respondent perceived greater confidence in resisting smoking in the context.

    Measured: Baseline

  6. Withdrawal symptoms

    The 9-item version of Minnesota Nicotine Withdrawal Scale (MNWS) was used for detection of withdrawal symptoms, which was revealed to have two domains of negative affect and insomnia and three individual items. Participants rated the symptoms by using a 5-point Likert-type (0=not present to 4=severe). Higher values of the MNWS indicate more severe nicotine withdrawal symptoms.

    Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Mar 2024
  2. Study start5 Apr 2024
  3. Primary completion31 Jan 2025
  4. Study completion15 Apr 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
567 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06303089
Sponsor's protocol ID
zzwee-quit (CKD) 23152
Status last verified
Apr 2025
First submitted
4 Mar 2024
Last updated
23 Apr 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The non-identified individual participant data will be shared after the outcomes have been published.

Questions about this trial

What is this clinical trial studying?

An observational study of Smoking Cessation, run by Sun Yat-sen University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Prevalence of current smokers (time frame: Baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in